Biosimilars in the therapy of inflammatory bowel diseases
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Gastroenterology,Hepatology
Reference28 articles.
1. Use of infliximab in the treatment of Crohns disease in children and adolescents.;Hyams;J Pediatr,2000
2. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.;Curtis;Clin Ther,2011
3. Development and regulation of biosimilars: current status and future challenges.;Tsiftsoglou;BioDrugs,2013
4. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs.;Crommelin;Int J Pharm,2003
5. European perspective on biosimilars.;Wadhwa;Bioanalysis,2013
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort;United European Gastroenterology Journal;2023-02-17
2. Challenges for biosimilars: focus on rheumatoid arthritis;Critical Reviews in Biotechnology;2020-10-11
3. Bilateral Sub-deltoid Bursitis in a Patient Receiving Infliximab for Crohn's Disease;Current Drug Safety;2020-02-03
4. Long‐term efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study;Journal of Gastroenterology and Hepatology;2019-03-18
5. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN;Journal of Pediatric Gastroenterology & Nutrition;2019-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3